- CODEN : IAJPBB
- issn 2349-7750
TITLE:
COMMON SIDE EFFECTS AND LEADING CAUSE OF DISCONTINUATION OF METHOTREXATE IN RHEUMATOID ARTHRITIS PATIENTS
AUTHORS:
Dr Sidra Shaheen, Dr Sahrish Batool, Dr Muhammad Zulqarnain
ABSTRACT:
Aim: To evaluate frequency and to identify factors which may increase the discontinuation of Methotrexate (MTX) among Rheumatoid arthritis (RA) patients. Place and Duration: In the Rheumatology Department of Fatima Memorial Hospital, Lahore for one year duration from March 2019 to February 2020. Methods: A cross-sectional study was conducted in the Rheumatology Department of Fatima Memorial Hospital, Lahore in subjects that are currently or previously were using MTX. All the patients were included who fulfilled the 1987 revised American Rheumatism Association criteria for classification of RA. Medical records for 200 RA patients were chosen through convenience method then they reviewed Results: The study involved 200 RA patients, 169 (84.5%) were women, 31 (15.5%) were women. Their age is between 12 and 80 years, on average 45.07 and standard deviation 14.37 years. Approximately 67 (33.5%) patients stated that the disease duration was 10 years and more, and 147 (73.5%) patients used MTX and 53 (26.5%) did not use the drug. 24 of 147 patients (27%) did not receive MTX regularly for various reasons. The most common side effects are abdominal pain, laziness and laziness. There is no statistically significant relationship between sex, education level, duration of illness and interval p = 0.05. Conclusion: The study showed a low rate of discontinuation due to side effects, MTX appears to be a safe drug for long-term use in RA patients. More attempts should be made to minimize side effects and discontinuation of MTX to obtain the benefits of a cornerstone drug in the treatment of RA. Key words: Arthritis, Rheumatoid, Methotrexate, Rheumatic diseases
FULL TEXT
Approved Journal
NLM ID:101711216 [Serial]
Included in EuroPub database
ICV 2015 - 61.16
Indexed In
S.J Impact Factor:7.157
cosmos Impact Factor:4.153
ICMJE Recommendations
IP Indexing Impact Factor: 2.76
Cover Page
